Redx Halts Enrollment in Trial of Lead Candidate, Citing Adverse Events

Redx Pharma saw its stock price plunge 61% this morning, after disclosing that it has temporarily halted patient recruitment in the Phase I/IIa trial of its lead candidate, the cancer treatment RXC004, just a month after it launched.In a statement, Redx said it informed the U.K.’s Medicines and Healthcare products Regulatory Agency (MHRA) of the temporary halt. The company cited unspecified “clinically significant adverse events” being observed in the first patient dosed with R